Tuesday, April 16, 2024

Assessing Health-Related Quality of Life Outcomes in Relapsed or Refractory Large B Cell Lymphoma

Similar articles

In the rapidly evolving field of treatment for relapsed or refractory (R/R) large B cell lymphoma (LBCL), a comprehensive understanding of health-related quality of life (HRQOL) outcomes is crucial. These outcomes can directly influence the treatment options available to patients and physicians. Current healthcare policy and decision-making assessments often lack consolidated health-related quality of life outcomes and utility reports for both old and new products in this field.

A systematic literature review (SLR) was conducted to gather HRQOL evidence for R/R LBCL treatments and identify associated health utility values. The SLR covered literature published from January 2003 to May 2022, screening studies based on established criteria. Quality assessments of the evidence were conducted in line with health technology assessment recommendations from the National Institute for Health and Care Excellence. The review included various therapies, such as chimeric antigen receptor (CAR) T cell products and novel therapies.

Health-Related Quality of Life

Insights from a Comprehensive Review: Health-Related Quality of Life in Relapsed or Refractory Large B Cell Lymphoma

The review identified 33 unique studies that reported on HRQOL, including 15 economic studies that reported health state utility values, 9 clinical trials, 7 health technology assessment reports, and one each of a vignette-based study and a point-in-time survey. CAR T cell therapy was observed to lead to improvements in general and/or lymphoma-specific HRQOL measures in both the second-line and third-line or later settings.

The on-treatment utility values for CAR T cell therapies ranged from 0.50 to 0.74. Remission/progression-free survival values were similar across studies (0.70-0.90), as were values for disease progression (0.39-0.59). For novel therapies, utility values were 0.83 for progression-free survival and ranged from 0.39 to 0.71 for disease progression. On-treatment utility values for salvage chemotherapy ranged from 0.63 to 0.67.

In conclusion, the evidence synthesized in the SLR offers a comprehensive understanding of the HRQOL evidence in R/R LBCL. The study identified sources for utility values in the published literature, showing variation in HRQOL outcomes for patients across various therapeutics. Treatment of R/R LBCL with CAR T cell therapies was associated with improvements in health utility values. However, mixed results were found for novel therapies and salvage therapies. More data is needed as new therapies emerge for this patient population to guide treatment decision-making.

 

Original Article DOI: 10.1007/s41669-023-00464-5

Original title: A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article